Vireo Growth (VREOF) Non Operating Interest Expenses (2024 - 2025)
Vireo Growth (VREOF) posted Non Operating Interest Expenses of $607085.0 for Q3 2025, up 37.03% sequentially from $443031.0 in Q2 2025, and up 153.02% YoY from $239932.0 in Q3 2024.
Vireo Growth (VREOF) Non Operating Interest Expenses (2024 - 2025) Analysis & Trends
Vireo Growth has reported Non Operating Interest Expenses for 2 years, with the latest figure at $607085.0 in Q3 2025.
- Quarterly Non Operating Interest Expenses rose 153.02% year-over-year to $607085.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1.4 million (changed N/A YoY) and the FY2024 annual result came in at $859535.0, up 8.53% from the prior year.
- Non Operating Interest Expenses improved to $607085.0 in Q3 2025 per VREOF's latest filing, from $443031.0 in the prior quarter.
- Over five years, Non Operating Interest Expenses peaked at $607085.0 in Q3 2025 and troughed at $166542.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | -400.56 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 2.90 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 120.70 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 2.90 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Vireo Growth | 493.25 Mn | 350.95 Mn | 95.30 Mn | 7.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 607,085.00 |
| Jun 30, 2025 | 443,031.00 |
| Mar 31, 2025 | 166,542.00 |
| Dec 31, 2024 | 207,643.00 |
| Sep 30, 2024 | 239,932.00 |
| Jun 30, 2024 | 189,946.00 |
| Mar 31, 2024 | 222,014.00 |